February 24, 2017
Oncology focused drugmaker Xynomic Pharmaceuticals secures Abexinostat global rights
Oncology drug research and development company Xynomic Pharmaceuticals has acquired exclusive worldwide rights to develop a novel HDAC inhibitor targeting hematological and solid tumors, Abexinostat.